Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Campaigning in the early caucus state of Nevada, the 78-year-old Vermont senator said one of the things that disturbed him about Thursday’s debate was that he was hoping “to have a serious discussion about the health care crisis in America.” “I was not pleased that Vice President Biden distorted what Medicare for All is and, in fact, simply parroted the line coming from the health care industry,” Sanders told about 300 people at a town hall meeting at the Carson City Community Center gymnasium. “Apparently the vice president thinks it is just wonderful for people to be paying $1,000 a month ... just for health care premiums. Having deductibles of $4,000 or $5,000 or more — not a problem. Paying the highest prices in the world for prescription drugs — not a problem. Well, I think those are problems,” he said. Sanders took heavy fire on his single-payer health insurance proposal at Thursday night’s debate in Houston, with Biden and others hammering the Vermont senator for the cost and the political palatability of effectively eliminating the existing private insurance market. The former vice president went hardest at Sanders when the senator argued that the estimated $30 trillion cost over a decade is cheaper than the “status quo,” which he put at $50 trillion — with most of the money being what Americans spend privately on premiums, copays and out-of-pocket costs. Sanders’ argument is that most U.S. households would pay less overall under his system, even if their taxes go up. Biden said that Sanders would effectively be handing Americans a pay cut, arguing that employers who now pay a share of workers’ premiums would pocket that money instead of giving workers raises if the government were to cover all health care costs. Biden punctuated the point with one of the quotes of the night: “For a socialist, you’ve got a lot more confidence in corporate America than I do.” Biden has aggressively defended the Affordable Care Act that was created while he was vice president under President Barack Obama. Biden released a proposal in July to add a “public option” to the 2010 health care overhaul, with expanded coverage paid for by tax increases on the wealthiest Americans. Sanders repeated his refrain Friday that health care is a human right and that Medicare for All would cover every man, woman and child in the country. It requires no premiums, no deductibles and no out-of-pocket costs and would expand Medicare to include such things as dental care, hearing aids and home health care, he said. “It’s not a terribly radical idea because in one form or another it exists in countries all over the world, including Canada,” Sanders said. “Is it free? No. It is funded out of the general fund in a progressive manner.” Sanders said the primary function of the existing American health care system — the costliest in the world — is to make profits for drug and insurance companies. Sanders and a supporter of President Donald Trump — who said he recently lost his insurance and job — initially shouted over each other when Sanders asked for input from the audience. But they eventually put their arms around each other as Sanders asked him to help deliver the message to health care corporations and pharmaceutical drug companies that “the function of health care is to provide quality care to all of these people.” Sanders dismissed others who suggested Medicare for All would prevent people from selecting their own doctor. “You can go to any doctor you want,” Sanders said. “Anybody who tells you Medicare for All limits your choices of doctors are not telling you the truth.” Sanders lost the 2016 Democratic caucuses in Nevada to Hillary Clinton 55% to 45% primarily because of her strength in Las Vegas and Clark County but has maintained fierce support in the key Western swing state. He carried northern Nevada’s Washoe County, where he drew loud cheers later Friday from hundreds of students at an outdoor “College For All” rally on the campus of the University of Nevada, Reno. He also planned to campaign Saturday in Las Vegas.
Sanders accuses Biden of distorting ‘Medicare for All’ plan.

P&G, with roughly $68 billion in annual revenue, said it has invested millions in creating and testing refills for detergents over the years and is now trying to push in to mainstream beauty and body care refills – which are virtually  unheard of. It recently began offering some Olay face-cream jars with refill pouches on Olay.com, telling Reuters it has plans to expand the sales of the pouches in Europe early next year. “We’re learning on our legs so I don’t know that we’re in a position to say, ‘Hey, here’s the magic to selling refills,’” P&G spokesman Damon Jones said. Beauty products retailer The Body Shop, owned by Brazil’s Natura Cosmeticos SA NATU3.SA, says it plans to roll out “refill stations” in its stores globally next year, allowing shoppers to buy reusable metal containers to fill with Body Shop shower gels or creams. The company had offered refills at its stores in the early 1990s, but discontinued them in 2003, citing a lack of consumer demand. Unilever, which has set targets for reducing and recycling plastic by 2025, in October announced the planned launch of “refill sticks” of deodorants under its Dove line of personal care products on Loopstore.com. The website, operated by recycling company TerraCycle, offers consumers the chance to buy some household products in ultra-durable packaging with refills delivered to their doors, milkman-style. Across the consumer goods industry, results for refillable products have been mixed so far as many shoppers are far too set in their ways to be easily weaned from living in a throwaway culture. While refills are less expensive to purchase - generally priced at 20% to 30% less per item than the containers they are aimed to replenish, according to Unilever - shoppers have so far, for the most part, failed to snap them up, the companies said. SC Johnson & Son Inc, marketer of Windex and Pledge, said refills and concentrates so far have not played well with either Americans or Europeans over the decade they have been offered, with unit sales of such products pretty much flat. It pulled concentrated refills for Shout stain remover off the shelves because they were not selling very well. In 2010, Unilever put 20-liter tanks to dispense detergents in Walmart Inc’s (WMT.N) British supermarket chain Asda, and provided flexible pouches for customers to refill. But with leaky machines, safety and maintenance problems and the high costs of upkeep, Unilever said the tests fell short of expectations. Asda was also unhappy because the tanks occupied a lot of space. “None of them sell very well – it is a convenience issue,” SC Johnson CEO Fisk Johnson told Reuters. Johnson said some people find it painstaking to wash and refill bottles themselves while others worry that smaller bottles filled with concentrates are less “bang-for-your-buck” than the larger ones they have used for years. Still, the privately held company said it was expanding its refill offerings this year to address concerns surrounding plastic waste and is also testing refill stations for cleaning products with UK retailer Waitrose, owned by Britain’s John Lewis [JLPLC.UL]. The Waitrose tests are showing the first signs of progress in refill sales, Johnson said, and the company is now thinking of expanding the project. Even if consumers are comfortable using refills for some household goods, it is more complicated to sell them for products like Pantene shampoo and Olay creams, P&G spokesman Jones said. For instance, with beauty products, the look and feel of packaging is a big factor in creating and maintaining customer loyalty, while delivering an environmental benefit, he said. Some shoppers say they want to buy refillable products, but that the offerings are not available at many stores. Earlier this year, dozens of consumers took to social media to urge The Body Shop to bring back its refill counters. “Refill, refill, refill!” Twitter user @JaiChipperfield said on July 22, joining a thread in which several other shoppers demanded the return of refills. “Seems to me that judging by these comments your customers want to see the return of refills,” @JaiChipperfield added. “Me too, it would be brilliant to see that return.”  The Body Shop eventually responded to those pleas. “Now with the renewed focus on sustainability, we believe it is the right time to return with it,” Body Shop spokeswoman Lucy Muircroft told Reuters this week.
Procter & Gamble, rivals take refills into beauty aisle.

The Food and Drug Administration cleared a near-copy of the drug, dubbed Amjevita, developed by Amgen Inc. Regulators approved the drug for more than a half-dozen conditions listed on the original drug’s label, including severe psoriasis and Crohn’s diseases. Humira posted sales of nearly $15 billion in 2015 and was for many years the top-selling prescription drug in the world, according to data from IMS Health. It’s the fourth time that the FDA has formally approved a so-called biosimilar, the industry term for a lower-cost version of a biotech drug. Biosimilar drugs, long available in Europe, are thought to have the potential to generate billions in savings for the U.S. health system. But currently only one biosimilar cleared by the FDA approval pathway is actually on the market in the U.S., Novartis’ Zarxio, an alternative to Amgen’s Neupogen that sells for about 15 percent less than the original product. The drug helps boost red blood cells in cancer patients. Amgen did not discuss plans for the drug’s launch or price in a release issued Friday evening. But Wall Street analysts have noted that AbbVie claims it holds patents protecting Humira until at least 2022. They have previously estimated that Amgen’s version could launch sometime between 2018 and 2022, depending on the outcome of court litigation. First approved in 2002, Humira accounted for 60 percent of AbbVie’s total revenue last year. The injectable drug, which blocks chemicals linked to inflammation, is part of a family of biotech drugs including Enbrel and Remicade, which are also facing pending biosimilar competition. Development of lower-cost anti-inflammatory drugs is considered pivotal in reducing U.S. spending on specialty drugs, which has doubled to $150 billion since 2010, according to IMS Health. Thousand Oaks, California-based Amgen is itself a biotech powerhouse, and it too has medications facing competition from cheaper versions. The company is working to hedge those loses by developing lower-cost versions of competitors’ drugs. AbbVie Inc. is based in North Chicago, Illinois.

FDA approves lower-cost alternative to biotech drug Humira.